An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Bevacizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms TASCO1 study
- Sponsors IRIS
- 04 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 06 Jul 2016 Planned End Date changed from 1 Mar 2019 to 1 Apr 2019.
- 06 Jul 2016 Planned primary completion date changed from 1 Mar 2019 to 1 Apr 2019.